Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001438533-21-000053
Filing Date
2021-10-29
Accepted
2021-10-28 21:58:21
Documents
85
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tvtx-20210930.htm   iXBRL 10-Q 1720546
2 EX-10.1 ex09302021101viforagreement.htm EX-10.1 651569
3 EX-31.1 ex09302021311.htm EX-31.1 12815
4 EX-31.2 ex09302021312.htm EX-31.2 12489
5 EX-32.1 ex09302021321.htm EX-32.1 8874
6 EX-32.2 ex09302021322.htm EX-32.2 8944
12 GRAPHIC tvtx-20210930_g1.gif GRAPHIC 205969
  Complete submission text file 0001438533-21-000053.txt   8910685

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tvtx-20210930.xsd EX-101.SCH 46624
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tvtx-20210930_cal.xml EX-101.CAL 88640
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tvtx-20210930_def.xml EX-101.DEF 258435
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tvtx-20210930_lab.xml EX-101.LAB 588895
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tvtx-20210930_pre.xml EX-101.PRE 404366
13 EXTRACTED XBRL INSTANCE DOCUMENT tvtx-20210930_htm.xml XML 1300190
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

EIN.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36257 | Film No.: 211360450
SIC: 2834 Pharmaceutical Preparations